Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from lopinavir/ritonavir + tenofovir disoproxil fumarate + lamivudine to dolutegravir + lamivudine in virologically suppressed adults with HIV-1
ChiCTR2000034717Phase 4Recruiting
- Sponsor
- Zhengzhou Sixth People's Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by Zhengzhou Sixth People's Hospital. Primary endpoints: HIV viral load, alkaline phosphatase and 10 more. Started Jul 2020; status: recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2000034717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034717.